Spontaneous Remission In Burkitt? Lymphoma
National Cancer Institute Monographs 44: 1976; 61-65
View Original Source →Abstract
Accumulated evidence suggests that human neoplasms contain antigens that elicit humoral and cellular immunity in the immunocompetent host. A recent summary report showed that Stage II melanoma patients with metastases to regional lymph nodes had a lowered incidence of recurrence and a higher incidence of survival following surgery and postoperative BCG immunotherapy. To verify these findings, clinical trials are now under way in which we randomized melanoma patients into groups to compare treatment by surgery alone with surgery and BCG only, or surgery and BCG in combination with allogeneic melanoma cell vaccine. Serum samples from each patient are monitored by in-vitro techniques to define those methods which best correlate to clinical course. Hopefully, such correlations can be used to monitor response to immunotherapy before disease is clinically apparent. Although immunotherapy does not cause regression of far-advanced disease, it undoubtedly will be beneficial against subclinical, microscopic tumor.
Case Details
Remission Characteristics
Spontaneous regression
Treatment & Mechanisms
Proposed Remission Mechanisms
Antitumor immunity
Additional Notes
Three cases of spontaneous regression of Burkitt? lymphoma are reviewed and additional clinical and laboratory observations relevant to the role of host defences are summarized.